Five years ago, fundamental changes began in Russian healthcare, one of which was the creation of large national medical research centers. At the suggestion of Minister Veronika Skvortsova three well-known and respected institutions united. In 2014 P. Hertsen Moscow Oncology Research Institute, N. Lopatkin Scientific Research Institute of Urology and Interventional Radiology, A. Tsyb Medical Radiological Research Centre merged into National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation (NMRRC). Of course, at the beginning of the journey there was a lot of reflection on how to preserve the best in this new configuration and not to lose tradition. Today, when the problem of the fight against cancer around the world has come to the fore, and has become a national priority in our country, we understand how timely the decision to create the first such oncology cluster in Russia was. Today, our joint center employs more than three thousand people, we perform more than 16,000 operations per year, more than 3,000,000 studies, and we test a large number of new medicines and modern techniques. Our specialists perform unique operations: completely restore speech and normal functions of the tongue, pharynx, larynx from the biomaterial of the patient himself; we carry out radioembolization with the help of domestic microspheres developed by our centre, we do brachytherapy on the liver and pancreas using the domestic radioisotope iodine 125.Show
Proper routing between the branches of the Center allows a patient who comes to us to receive a full range of combined and complex diagnostic and treatment procedures, including surgery, various options for chemotherapy and radiation therapy. There are wide opportunities for international cooperation - we give our expert opinion to colleagues from respected foreign cancer centers, with which we have signed several agreements on real collaborative projects over the past two years. A common telemedicine platform for exchanging morphological and clinical data is being created; we are planning to open the second proton therapy centre and the first heavy ion therapy center (in the post-Soviet states) in collaboration with Japanese colleagues. People come to us for experience and they are amazed to see the significant results we have been able to achieve in just five years. This has become possible thanks to the synergy of our merger and state support of oncology. Efficiency and targeting, proclaimed in the new national cancer control program, and multidisciplinarity in solving tasks have become a reliable basis for the implementation of the program.
I am sure we can do a lot together!
In 1898, funded by donations from Moscow merchants and initiated by greatest Russian scientists, a hospital-shelter for cancer-obsessed was built. It was named Morozov Institute. The first director of the institute was the famous professor Lev Lvovich Levshin.
The institute had 65 beds. Twice a week, the floors and ceilings were washed with water at a pressure of 3.5 atm. The operating room was sterilized with steam. A professor from Leiden University who visited the institute said that it was one of the best oncological institutions in Europe.
In 1922, the institute was headed by Pyotr Alexandrovich Herzen. Being a talented scientist, surgeon and having an extraordinary personality, he generated ideas and brought them to life. Pyotr Herzen radically changed the nature of oncological activity - from palliative care to radical treatment.
P. Hertsen Moscow Oncology Research Institute - branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation is the first oncological scientific and practical institution in Europe and the first oncological hospital in Russia, where the foundations of oncological science and service were laid. It specializes in different types of treatment for cancer patients: surgery, radiation therapy, chemotherapy, photodynamic therapy and combination therapy; develops and puts into practice new methods of diagnosis and treatment that improve prognosis and quality of life after treatment.
The scientific sector of the Institute studies etiology and pathogenesis of mechanisms of carcinogenesis, as well as the development of methods for prevention, diagnosis, surgical treatment, radiation therapy, chemotherapy, combination therapy for malignant tumors.
With more than 120 years of experience, the Institute offers residency and postgraduate programs and provides additional professional education. Annually, more than 1,000 doctors from all over Russia study and improve their qualifications here.
P. Hertsen Moscow Oncology Research Institute has a high scientific potential. It has brought up a galaxy of scientists who are engaged not only in fundamental developments and their application in practice, but also in the creation of new anticancer drugs and conservative treatment methods in order to improve the quality of the patient’s life. The highly professional team employs 275 doctors of the highest qualification grade, including 38 Doctors of Medical Sciences and 162 PhDs.
• Over 60,000 patients receive outpatient care
• More than 16,000 patients receive inpatient care
• More than 7,000 patients receive treatment using high-tech medicine
• Over 5,000 surgeries
• 1,500,000 laboratory tests
• 90,000 diagnostic tests
21st century surgery is highly susceptible to the achievements of fundamental science of oncology and the results of conservative treatment methods. P. Hertsen Moscow Oncology Research Institute is an expert center in oncosurgery not only in the Russian Federation and CIS countries, but also in Europe. The leaders of the Institute are members of many professional societies and regional committees. Every month, demonstration operations from the operating rooms of the Institute are broadcast on the Internet. The Institute is highly successful in performing minimally invasive surgery in oncogynecology and oncourology, video-assisted lobectomy and segmentectomy, resections of the stomach and esophagus, colon, liver, and mediastinal tumors. Today surgical oncologists are also plastic surgeons. In the departments of oncommammology, women undergo simultaneous oncological and plastic surgery, which is aimed at solving important issues of aesthetics and social rehabilitation. Employees of P. Hertsen Moscow Oncology Research Institute understand that their biggest success is recovered patients. Surgeons’ love for work, responsibility and loyalty to traditions have ensured the leadership of the Institute in oncosurgery for more than 100 years.
The range of the equipment for radiation therapy at P. Hertsen Moscow Oncology Research Institute is extremely wide, which allows performing irradiation of tumors of any volume and configuration located at any depth.
The Institute has unique devices for various types of radiation therapy: four electron accelerators Elekta Axesse, Elekta Infinity, Siemens Oncor, as well as the CyberKnife robotic system and the MULTISOURCE brachytherapy device.
In 2018 more than 2,300 patients with tumors of the head and neck, lung, esophagus, brain, breast, rectum, prostate, gynecological tumors were treated in the Institute. Doctors use all latest radiotherapy technologies available in the world: 3D-CRT - three-dimensional conformal radiation therapy, IMRT - intensity modulated radiation therapy, VMAT - Volumetric modulated arc therapy, IGRT - Image-guided radiation therapy, SBRT - Stereotactic body radiation therapy, SRS - stereotactic radiosurgery.
Russian reconstructive microsurgery is 76 years old. The first specialized Otolaryngology department was established at P. Hertsen Moscow Oncology Research Institute in 1943. Today, our specialists for Reconstructive Microsurgery of the Head and Neck are highly respected not only in Russia but also in the world. The most complex reconstructive technologies in the treatment of tumors of all localizations are being actively introduced into clinical practice. Twice the Institute’s Microsurgery Department has been awarded state prizes for the development of organ-preserving treatment in oncology.
New technologies are being developed for reconstruction of the facial skeleton after malignant tumors, reconstruction of the upper sections of the aero digestive tract using complexes of the abdominal cavity and visceral autotransplants. Microotorinolaryngeal surgery of early laryngeal cancer is widely used. Cellular biotechnologies and bioengineering methods are being introduced and developed to reconstruct the oropharyngeal region of the upper digestive tract in order to create autologous structures lost as a result of tumor removal.
In P. Hertsen Moscow Oncology Research Institute the latest endoscopic technologies for diagnosis and treatment are actively used. Near-focus narrow-band imaging endoscopy, confocal laser endomicroscopy and endocytoscopy can detect precancerous conditions and early forms of cancer of the esophagus, stomach, colon and bronchial tree with lesions smaller than 1 mm. Using these methods the doctors can also predict the histological structure of the neoplasm without biopsy (with the help of endoscopic ultrasonography to assess the depth of tumor spread into the organ wall), determine the structure of submucosal neoplasms and visualize the affected lymph nodes.
Up-to-date methods of organ-preserving intraluminal endoscopic tumor removal are also actively used: endoscopic mucosal resection with dissection in the submucosal layer, endoscopic photodynamic therapy, argon-plasma coagulation. These methods allow removing tumors without incisions and punctures, directly through the endoscope.
The method of pressurized intraperitoneal aerosol chemotherapy (PIPAC) was invented in Germany, however, this technique has been introduced into clinical practice only in the Russian Federation at P. Hertsen Moscow Oncology Research Institute. This is the latest innovative treatment for peritoneal carcinomatosis.
PIPAC is the method of delivering chemotherapy medicine directly to tumor cells located on the inner lining of the anatomical cavity. It is a minimally invasive laparoscopic surgery.
Chemotherapy aerosol is sprayed in the abdominal or pleural cavity under the pressure of carbon dioxide and left for 30 minutes. With this method of administering chemotherapy drugs, their effect on the tumor increases many times in the complete absence of systemic toxicity.
The peculiarity of this method in P. Hertsen Moscow Oncology Research Institute is that the specialists have developed a nozzle for delivering the chemotherapy drug into the abdominal cavity, which forms a stream of fine aerosol with the droplet size from 1 to 40 microns.
Modern chemotherapy strategies allow us to achieve long-term complete remission (recovery) in a significant number of patients with various types of lymphomas. However, in some patients, the use of standard doses of chemotherapy drugs does not allow achieving complete destruction of the tumor or the antitumor effect is short-term, i.e. some time after the end of treatment, a relapse of the disease may develop. In such cases, second line induction chemotherapy (3-4 courses) is carried out and then, at the peak of the effect of this treatment, it becomes necessary to carry out high-dose consolidation, followed by autologous hematopoietic stem cell transplantation (auto-HSCT).
According to modern clinical guidelines for the diagnosis and treatment of multiple myeloma, high-dose chemotherapy with auto-HSCT should be used as a consolidation in primary patients (without serious concomitant pathology, younger than 65 years old) after first line induction chemotherapy.
The methods of fluorescence diagnostics (FD) and photodynamic therapy (PDT) were first used in clinical practice in Russia in 1992 at P. Hertsen Moscow Oncology Research Institute. In the following years, the Center for Laser and Photodynamic Diagnosis and Treatment of Tumors was established at the Institute. The centre is a scientific, educational and methodological base for the introduction of FD and PDT methods in the regions of Russia.
FD methods can even detect hidden foci of early cancer on the surface - either the mucous membrane or the skin. The use of these methods leads to the increase of the detection of early cancer.
The PDT methods developed at the Center are successfully used in the treatment of precancerous conditions - actinic keratosis, dysplasia of the cervix, vulva, and mucous membrane of hollow organs. PDT is effective in the treatment of early cancer of various localizations: skin, esophagus, stomach, cervix, vulva, bladder, etc. In addition, the PDT method effectively helps even in cases where other methods of antitumor treatment are not applicable or ineffective: with palliative treatment of patients with stenosing cancer of the esophagus, cardia and other localizations.
The initiator of the creation of the national cancer registry in Russia was the outstanding Russian scientist, professor, surgeon Lev Lvovich Levshin, who was the first to begin experimental research in the field of carcinogenesis. In 1901, he sent out 15,000 registration cards to register cancer patients, which made him the founder of statistics in oncology. Today, the population cancer registry is an Information and Analytical System (IAS “Cancer Registry”) for collecting, storing and analyzing information about malignant neoplasms among the population of the Russian Federation.
Annually, IAS “Cancer Registry” issues two bulletins: on the state of morbidity and mortality in the Russian Federation and on the state of cancer care for the population of Russia.
The Cancer Atlas (Second Edition, American Cancer Society, 2014) ranks the National cancer registry of the Russian Federation as a high-quality regional registry.
3,630,567 patients are registered in oncology clinics of the Russian Federation.
In 2018, 615,177 new cases of cancer were detected.
The absolute number of deaths from cancer in 2018 amounted to 155,754.